170
Participants
Start Date
June 19, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2027
BH-30236
BH-30236 will be provided as either a 5 mg, 15 mg or 30 mg tablet. Participants will take BH-30236 tablets orally depending on their dose level assignment.
Venetoclax
Venetoclax will be provided as 10 mg, 50 mg or 100 mg tablets. Participants will take venetoclax orally per label instructions.
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Roswell Park Cancer Institute, Buffalo
RECRUITING
Sylvester Comprehensive Cancer Center, Miami
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Sarah Cannon Research Institute, Nashville
RECRUITING
The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
RECRUITING
University of Wisconsin Clinical Science Center, Madison
RECRUITING
Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
RECRUITING
The University of Texas M.D. Anderson Cancer Center, Houston
RECRUITING
University of California Los Angeles, Los Angeles
RECRUITING
City of Hope Medical Center, Duarte
RECRUITING
Stanford Cancer Center, Palo Alto
RECRUITING
Fred Hutchinson Cancer Center, Seattle
Lead Sponsor
BlossomHill Therapeutics
INDUSTRY